Literature DB >> 9099449

The effect of food on the pharmacokinetics of multiple-dose terbinafine in young and elderly healthy subjects.

J Nedelman1, J A Cramer, B Robbins, E Gibiansky, C T Chang, S Gareffa, A Cohen, J Meligeni.   

Abstract

Pharmacokinetic (PK) parameters for terbinafine were assessed in 15 elderly and 15 young healthy subjects randomized to receive 250 mg Lamisil once daily for 15 d in a two-period, two-treatment, two-sequence, crossover (fed versus fasted) design within age groups. On each treatment day except days 8 and 15, subjects took Lamisil with food at 8:00 a.m. On days 8 and 15, subjects took the drug under either fed or fasting conditions according to treatment sequence, and 24 h PK profiles were obtained. Two analyses of the pharmacokinetic data were undertaken. In a noncompartmental analysis, AUC0-24h, Cmax, C0h, and tmax were computed for each subject on each of days 8 and 15, and the influences of food condition and age on these variables were assessed by analysis of variance. AUC0-24h and C0h were found to be larger (p < 0.5) among elderly subjects than young subjects on day 15, and tmax was prolonged (p < 0.05) under the fed condition on day 15. Similar trends on day 8, as well as generally higher exposures under the fed condition on both days, were not statistically significant. A three-compartment model fitted to the complete sequence of 33 terbinafine concentrations measured over 29 d for each subject separately permitted a within-subject assessment of the food effect that confirmed prolonged absorption and increased bioavailability (p < 0.05) under the fed condition. Across-subject comparisons of oral clearances estimated with the model also confirmed the increased exposures (lower clearances) among the elderly (p < 0.05). The drug was well tolerated in both age groups. In particular, greater drug exposure in the elderly did not result in greater toxicity, as indicated by the safety evaluations in the study.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9099449     DOI: 10.1002/(sici)1099-081x(199703)18:2<127::aid-bdd6>3.0.co;2-8

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  8 in total

1.  Terbinafine in combination with other antifungal agents for treatment of resistant or refractory mycoses: investigating optimal dosing regimens using a physiologically based pharmacokinetic model.

Authors:  Michael J Dolton; Vidya Perera; Lisa G Pont; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2013-10-14       Impact factor: 5.191

Review 2.  Human pharmacogenomic variations and their implications for antifungal efficacy.

Authors:  Joseph Meletiadis; Stephen Chanock; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

Review 3.  Pharmacokinetics of antifungal agents in onychomycoses.

Authors:  D Debruyne; A Coquerel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

4.  Use of terbinafine in mouse and rat models of Pneumocystis carinii pneumonia.

Authors:  Peter D Walzer; Alan Ashbaugh
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 5.  Terbinafine. An update of its use in superficial mycoses.

Authors:  K J McClellan; L R Wiseman; A Markham
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

Review 6.  Effects of food on clinical pharmacokinetics.

Authors:  B N Singh
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

7.  Physiologically based pharmacokinetic model for terbinafine in rats and humans.

Authors:  Mahboubeh Hosseini-Yeganeh; Andrew J McLachlan
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

8.  Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality.

Authors:  Boni Elewski; Amir Tavakkol
Journal:  Ther Clin Risk Manag       Date:  2005-12       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.